Remove Diabetes Remove Families Remove Individual Remove Manufacturing
article thumbnail

Degree of Weight Loss Affects Tirzepatide-Linked Cardiometabolic Risk Improvement

Physician's Weekly

“Understanding whether there are specific thresholds of weight reduction associated with minimum or maximum cardiometabolic benefits may assist clinicians in tailoring weight reduction goals to individual patients seeking to reduce their cardiometabolic risk,” the authors write. Bruno Linetzky, M.D.,

article thumbnail

How to Get Ozempic & GLP-1’s Covered by Insurance (or Save Big with Plum Health Direct Primary Care): The Ultimate Guide You Can’t Afford to Miss!

Plum Health

Managing diabetes—especially as you get older—can be challenging physically, emotionally, and financially. If you’re living with Type 2 diabetes, you’ve probably heard of Ozempic, Wegovy (semaglutide), Mounjaro or Zepbound (tirzepatide). With Plum Health, managing your diabetes becomes easier, more affordable, and less stressful.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Maine and Nevada Update Drug Price Transparency Laws

FDA Law

Schlanger — Maine and Nevada previously enacted laws requiring drug manufacturers to report information about the pricing of their products. Both states’ new requirements will become effective in October 2021 and should be considered as manufacturers prepare for state drug price transparency reporting in 2022.

article thumbnail

Hearing Loss in Geriatrics and Palliative Care: A Podcast with Nick Reed and Meg Wallhagen

GeriPal

We talk with Nick and Meg about: Why hearing loss is important not just in geriatrics but also for those caring for seriously ill individuals. Communication techniques we can use when talking to individuals with hearing loss. And he liked some of what I was doing, which was really on diabetes and hearing loss.

IT 102